RO106-9920

RO106-9920 is a selective small molecule inhibitor of the nuclear factor kappa B (NF-κB) signaling pathway. It functions by selectively inhibiting the ubiquitination of IκBα, which prevents its degradation and the subsequent nuclear translocation and activation of the NF-κB transcription factor. By blocking this pathway, RO106-9920 effectively suppresses the expression of NF-κB-dependent pro-inflammatory cytokines (such as IL-6 and IL-8) and adhesion molecules (such as ICAM-1 and VCAM-1). Originally developed by Roche, it is widely utilized as a pharmacological tool in research to investigate the role of NF-κB in various pathological processes, including vascular aging, inflammation, and neurodegenerative conditions like Alzheimer's disease and vascular dementia.